Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
APDN 
Applied DNA Sciences Inc (APDN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: APDN (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $1.5
1 Year Target Price $1.5
| 0 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -83.21% | Avg. Invested days 33 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 2.51M USD | Price to earnings Ratio - | 1Y Target Price 1.5 |
Price to earnings Ratio - | 1Y Target Price 1.5 | ||
Volume (30-day avg) 1 | Beta 0.05 | 52 Weeks Range 4.37 - 2655.00 | Updated Date 06/29/2025 |
52 Weeks Range 4.37 - 2655.00 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 3730.95 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -194.18% | Operating Margin (TTM) -352.03% |
Management Effectiveness
Return on Assets (TTM) -73.41% | Return on Equity (TTM) -148.66% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -3859670 | Price to Sales(TTM) 0.66 |
Enterprise Value -3859670 | Price to Sales(TTM) 0.66 | ||
Enterprise Value to Revenue 0.88 | Enterprise Value to EBITDA -0.34 | Shares Outstanding 519000 | Shares Floating 429001 |
Shares Outstanding 519000 | Shares Floating 429001 | ||
Percent Insiders 2.76 | Percent Institutions 4.12 |
Analyst Ratings
Rating 1 | Target Price 1.5 | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Applied DNA Sciences Inc
Company Overview
History and Background
Applied DNA Sciences Inc. was founded in 1983. Initially focused on DNA research, the company evolved to specialize in DNA-based security and authentication solutions. Key milestones include developing SigNature DNA for anti-counterfeiting and expanding into therapeutic DNA production.
Core Business Areas
- DNA Manufacturing Services: Offers DNA manufacturing services, including PCR-based DNA for diagnostics, therapeutics, and industrial applications.
- DNA Security Solutions: Provides DNA-based security and authentication solutions to protect products from counterfeiting and diversion.
- Molecular Tagging: Develops molecular tagging systems for product authentication and supply chain tracking.
Leadership and Structure
Dr. James Hayward is the President and CEO. The company has a board of directors and is structured into functional departments such as R&D, sales, and operations.
Top Products and Market Share
Key Offerings
- SigNature DNA: A DNA-based marker used to authenticate products and trace them back to their source. Market share data is not publicly available but is used globally across various industries. Competitors include SICPA and Authentix.
- LinearDNA: A PCR-free DNA manufacturing platform. Number of users is growing, but specific data is not publicly disclosed. Competitors include Aldevron and GenScript.
- COVID-19 Testing: Offering PCR-based COVID-19 testing services. The revenue contribution from this service is decreasing. Competitors include Quest Diagnostics and Labcorp.
Market Dynamics
Industry Overview
The authentication and supply chain security market is growing due to increasing concerns about counterfeiting and product diversion. The therapeutic DNA manufacturing market is also expanding, driven by advancements in gene therapy and mRNA vaccines.
Positioning
Applied DNA Sciences Inc. occupies a niche position with its DNA-based authentication and manufacturing solutions. Its competitive advantage lies in its patented DNA marking technology and PCR-free DNA manufacturing platform.
Total Addressable Market (TAM)
The TAM for DNA-based security and therapeutic DNA is estimated to be in the billions of dollars. Applied DNA Sciences is positioned to capture a portion of this market through its proprietary technologies and strategic partnerships.
Upturn SWOT Analysis
Strengths
- Patented DNA marking technology
- PCR-free DNA manufacturing platform
- Expertise in DNA-based security
- Established relationships with key customers
Weaknesses
- Limited financial resources
- Small market capitalization
- Reliance on a few key customers
- History of net losses
Opportunities
- Growing demand for anti-counterfeiting solutions
- Expansion into new markets and industries
- Partnerships with larger companies
- Increased adoption of DNA-based therapeutics
Threats
- Competition from larger companies with more resources
- Technological advancements that could render its technology obsolete
- Economic downturns that could reduce demand for its products
- Regulatory changes
Competitors and Market Share
Key Competitors
- SICPA
- Authentix
- Thermo Fisher Scientific (TMO)
- Danaher (DHR)
Competitive Landscape
Applied DNA Sciences has a competitive advantage in its DNA-based solutions, but faces significant competition from larger companies with greater resources and market reach. Success depends on innovation and strategic partnerships.
Major Acquisitions
Vitatex Biomedical GmbH
- Year: 2022
- Acquisition Price (USD millions): 0.68
- Strategic Rationale: To expand its PCR testing capabilities.
Growth Trajectory and Initiatives
Historical Growth: Historically, Applied DNA Sciences' growth has been volatile and significantly influenced by factors such as demand for its authentication services and, more recently, COVID-19 testing. Revenue has fluctuated due to these external events.
Future Projections: Future growth projections are highly dependent on the company's ability to expand its DNA manufacturing business and secure new contracts. Analyst estimates vary widely, reflecting the uncertainty surrounding the company's prospects. Refer to analyst reports for specific projections.
Recent Initiatives: Recent initiatives include expanding its LinearDNA manufacturing capacity and forging partnerships to commercialize its technologies.
Summary
Applied DNA Sciences is a niche player in DNA-based security and manufacturing. While its patented technology provides a competitive edge, the company faces challenges in achieving sustained profitability and competing with larger players. Expanding the DNA manufacturing business and securing strategic partnerships are critical for future growth. Monitoring cash flow and profitability is crucial.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Applied DNA Sciences Inc. SEC filings
- Company press releases
- Industry reports and market research
- Analyst reports
Disclaimers:
This analysis is based on available information and is not financial advice. Market conditions and company performance are subject to change. Verify with current SEC Filings.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Applied DNA Sciences Inc
Exchange NASDAQ | Headquaters Stony Brook, NY, United States | ||
IPO Launch date 2003-07-15 | President, CEO, Chairperson & Secretary Ms. Judith Murrah | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 46 | Website https://www.adnas.com |
Full time employees 46 | Website https://www.adnas.com | ||
Applied DNA Sciences, Inc., a biotechnology company, develops and commercializes technologies to produce and detect deoxyribonucleic acid (DNA) in the Americas, Europe, Asia, and internationally. It operates through three segments: Therapeutic DNA Production Services; MDx Testing Services; and DNA Tagging and Security Products and Services. The Therapeutic DNA Production Services segment develops and commercializes the LinearDNA platform, which enables a cell-free manufacture of high-fidelity synthetic DNA sequences for use in nucleic acid-based therapeutics. The MDx Testing Services segment provides clinical molecular diagnostics (MDx) testing and clinical laboratory testing services; COVID-19 testing services, including test scheduling, sample collection, and automated results reporting for higher education institutions, private clients, and businesses under the safeCircle trademark; polymerase chain reaction (PCR) for production and detection of DNA and RNA; and MDx test kits and related supplies, as well as Isotopic analysis testing services. The DNA Tagging and Security Products and Services segment offers SigNature Molecular Tags, which provides a methodology to authenticate goods within large and complex supply chains for materials, such as cotton, nutraceuticals, and other products; SigNify portable DNA readers and SigNify consumable reagent test kits; and fiberTyping, which uses PCR-based DNA detection to detect a product's naturally occurring DNA sequences for the purposes of product provenance authentication and supply chain security. The company was formerly known as Datalink Systems, Inc. and changed its name to Applied DNA Sciences, Inc. in 2002. The company was founded in 1983 and is headquartered in Stony Brook, New York.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.